Study to Find New RNA Biomarkers in Blood for Early Detection of Barretts Esophagus and Esophageal Adenocarcinoma

What this Trial Is About

Researchers are exploring new RNA biomarkers in the blood to improve early diagnosis of Barretts esophagus and esophageal adenocarcinoma, aiming to detect these conditions sooner and potentially improve survival rates. This observational study involves analyzing RNA from tissue and plasma samples to identify specific micro RNA and messenger RNA patterns associated with these diseases. The study begins with a proof-of-concept phase involving 20 patients to compare RNA profiles from two types of samples and RNA biotopes using advanced sequencing methods. Following this, a large validation group will confirm the findings, leading to development of a clinical-grade qPCR test. This test will then be evaluated in an independent patient cohort to assess its diagnostic potential. Participants will provide tissue and plasma samples for RNA analysis, allowing researchers to perform detailed data mining and build classifiers for disease detection and therapy response prediction. The primary outcomes include identifying plasma biomarkers over four years and therapy response markers over two years. Secondary outcomes focus on developing a qPCR test within one year. The study includes monitoring for infections, organ function, and other health factors, with a total participation period spanning several years for comprehensive evaluation.

Barrett's Esophagus and Esophageal Adenocarcinoma, Searching for Reliable Diagnostic RNA Plasma-based Biomarkers